arrow
H

Harald Krenzlin

department of neurosurgery
H指数:14
被引数:1,274

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Maximal resection improves survival in MGMT methylated very elderly glioblastoma patients

MGMT甲基化的超高龄胶质母细胞瘤患者最大范围切除可改善生存

2026-02-090
OA
Treatment differences in IDH–wildtype glioma – the impact of surgery and adjuvant therapy

IDH野生型胶质瘤的治疗差异——手术和辅助治疗的影响

2025-12-290
OAAI
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma

CAR-NK细胞疗法与免疫检查点抑制相结合在胶质母细胞瘤中诱导了NKT细胞反应

2025-03-180
OA
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma

ATLAS/NOA-29研究方案: 一项新诊断的颞叶胶质母细胞瘤前颞叶切除术与全切除术的III期随机对照试验

2025-02-200
OAAI
MODULATION OF THE INTRATUMORAL IMMUNE MICROENVIRONMENT BY LOCAL THERAPY WITH NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中,通过用HER2-TARGETED嵌合抗原受体工程化的自然杀伤细胞局部治疗与全身ANTI-PD-1检查点抑制相结合来调节肿瘤内免疫微环境

2024-11-110
PRE
A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中重复颅内注射单独使用HER2-TARGETED嵌合抗原受体并结合全身ANTI-PD-1检查点抑制的自然杀伤细胞

2024-10-170
PRE
Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas
2024-02-072
OAAI
Microsurgical Clipping of Unruptured Anterior Circulation Aneurysms-A Global Multicenter Investigation of Perioperative Outcomes

未破裂前循环动脉瘤的显微外科夹闭术——一项关于围手术期结局的全球多中心研究

2024-01-193
OAAI
Global Outcomes for Microsurgical Clipping of Unruptured Intracranial Aneurysms: A Benchmark Analysis of 2245 Cases

未破裂颅内动脉瘤显微手术夹闭的全球结果: 2245例病例的基准分析

2023-09-216
OAAI
Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations
2023-02-164
OAAI